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Abstract
Background: MicroRNAs (miRNAs), a class of small non-coding RNAs, are thought to serve as crucial regulators of
gene expression. Dysregulated expression of miRNAs has been described in various diseases and may contribute to
related pathologic processes. Our aim was to examine circulating miRNA-146a levels in newly diagnosed type 2
diabetes mellitus (new-T2DM) patients from a Chinese Han population.
Methodology/Principal Findings: Circulating miRNA-146a was extracted from plasma samples of 90 new-T2DM
patients and 90 age- and sex-matched controls. Quantitative PCR assessment revealed that circulating miRNA-146a
levels were significantly elevated in new-T2DM patients compared with controls. Participants in the highest tertile of
circulating miRNA-146a levels showed a notably higher risk for new-T2DM (crude OR 4.333, 95% CI, 1.935 to 9.705,
P = 0.001) than persons in the lowest tertile. Controlling for known risk factors and some biochemical indicators did
not attenuate the aforementioned association. In addition, receiver operating characteristic (ROC) curves generated
for miRNA-146a revealed an area under the curve (AUC) of 0.725 (95% CI, 0.651 to 0.799, P < 0.001). Moreover,
higher circulating miRNA-146a levels were significantly associated with higher plasma heme oxygenase-1 (HO-1)
concentrations (β coefficient = 0.131, P < 0.001) and lower HOMA-beta (β coefficient = -0.153, P = 0.015).
Conclusions/Significance: We found that circulating miRNA-146a levels were significantly elevated in new-T2DM
patients compared with healthy controls. Whether expression of circulating miRNA-146a holds predictive value for
T2DM warrants further investigations.
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Introduction
Since their discovery by Lee and colleagues [1], microRNAs
(miRNAs), a class of endogenous small non-coding RNAs, are
becoming increasingly recognized as crucial regulators in gene
expression networks [2,3]. They can function as translational
repressors by binding to the 3’ untranslated regions (3’ UTRs)
of target messenger RNAs (mRNAs) and promoting their
degradation and/or directing posttranscriptional repression
[2,4]. In the past several years, accumulating evidence
suggests that miRNAs are not only key regulators in normal
physiological processes, but also play an important role in the
pathologic processes of cardiovascular disease, diabetes, and
cancers [5–9]. Recently, extracellular miRNAs were shown to
have stable levels, and circulating miRNAs have been detected
in serum, plasma, salvia, urine, and other body fluids [10–12]. It
has been suggested that exosomes or protein complexes
protect circulating miRNAs from plasma endogenous RNases
[12–14]. Interestingly, the expression profiles of miRNAs have
been shown to differ considerably between patients and
healthy controls [15,16]. To date, miRNAs have been
investigated as biomarkers in several diseases [17,18]
including type 2 diabetes mellitus (T2DM) [19].
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T2DM is a global public health crisis, affecting millions of
people in both developed and developing countries. By 2030,
the number of diabetic patients worldwide is expected to reach
438 million, and the economic cost is projected at $490 billion
per year [20]. Pathogenesis of T2DM involves enhanced
oxidative stress caused by iron metabolism [21]. Heme
oxygenase-1 (HO-1) is the rate-limiting enzyme that degrades
heme to carbon monoxide (CO), ferrous iron and biliverdin,
finishing with catalysis by biliverdin reductase [22,23]. HO-1
seems to be a novel protective factor with potent anti-
inflammatory, anti-oxidant, and anti-proliferative effects [24].
Our previous research suggested that plasma HO-1
concentration was elevated in individuals with new-T2DM [25].
Among the miRNAs identified so far, miRNA-146a has been
shown to be involved in the expression of HO-1 [26]. To date,
there are limited data on the association between circulating
miRNA-146a levels and risk of T2DM. Therefore, our aim was
to examine circulating miRNA-146a levels in relation to risk of
T2DM and plasma HO-1 concentrations in a Chinese
population.
Methods
Study Population
This study included 90 new-T2DM cases and 90 age- and
sex-matched controls. Cases were recruited from patients
visiting the outpatient clinics of the Department of
Endocrinology of Tongji Hospital (affiliated with Tongji Medical
College) between March 2011 and June 2011. Controls came
from an otherwise unselected population undergoing routine
health examinations in the medical examination center of
Wuhan Pu’ai Hospital (also affiliated with Tongji Medical
College) between July 2011 and October 2011. The inclusion
criteria for both cases and controls were: age ≥30 years, body
mass index (BMI) <40, and no history of diagnosis of diabetes.
Individuals with any other clinically systemic acute or chronic
inflammatory diseases, acute respiratory infection, or cancers
were excluded. All subjects were of Chinese Han ancestry. The
study was performed in accordance with the Declaration of
Helsinki and approved by the Medical Ethics Committee of
Tongji Medical College. Written informed consent was obtained
from all subjects. A standard questionnaire was used to collect
information about age, sex, smoking, alcohol drinking, history
of hypertension, and family history of diabetes in first-degree
relatives. Standardized techniques were used for
anthropometric measurements including height (m) and weight
(kg). Body mass index (BMI) was calculated as [weight (kg)/
height (m)2]. All subjects underwent a general physical exam
the morning after an overnight fast, and fasting blood samples
were drawn for plasma separation.
Laboratory Measurements
Plasma levels for biochemical parameters, including fasting
plasma glucose (FPG), 2-h post-glucose load (OGTT2h),
fasting plasma insulin (FPI), total cholesterol (TC), triglycerides
(TG), high-density lipoprotein cholesterol (HDL-C), and low-
density lipoprotein cholesterol (LDL-C) were measured as
previously described [27]. Beta cell function (HOMA-beta) and
insulin resistance (HOMA-IR) as indicators of homeostasis
model assessment were utilized to assess the status of insulin
secretion and insulin action, respectively. HOMA-beta = 20*
FPI (mU/ml)/[FPG (mmol/l)-3.5], HOMA-IR = FPG (mmol/l)* FPI
(mU/ml)/22.5 [28]. Plasma HO-1 levels were determined using
the HO-1 human ImmunoSet Kit (EKS-800, Stressgen
Bioreagents; now Enzo Life Sciences, Farmingdale, NY, USA).
Ascertainment of New-T2DM
T2DM was diagnosed by fasting glucose and/or oral glucose
tolerance test (OGTT) according to the World Health
Organization criteria of 1998 [29]. Participants with fasting
plasma glucose ≥ 7.0 mmol/l (126 mg/dl) and/or OGTT2h ≥
11.1 mmol/l (200mg/dl) were designated as having T2DM.
Controls were subjects with fasting plasma glucose < 6.1
mmol/l (110 mg/dl) and OGTT2h < 7.8 mmol/l (140mg/dl). Self-
reported T2DM status was confirmed by OGTT results. None of
the participants reported taking any anti-diabetic medications.
MiRNA Expression from Plasma Samples
Bloods were collected from participants in EDTA-coated
tubes and processed for plasma isolation within 2 hours of
collection. MiRNAs were isolated from 300 μl of plasma using
the mirVana™ PARIS™ Kit (Applied Biosystems, Foster City,
CA, USA), which uses a denaturing and phenol chloroform
extraction approach. Briefly, 300 μl of plasma was added to an
equal amount of denaturing solution and incubated on ice for 5
minutes. Afterwards, 600 μl of acid-phenol chloroform solution
was added to the samples to inhibit the activity of RNAases
and accelerate the separation of layers. The aqueous phase
was passed through glass-fiber filters to immobilize the RNA,
which was washed a few times and eluted with a low ionic-
strength solution, yielding a final volume of 80 μl. Then the
TaqMan MicroRNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, USA) was used for reverse
transcription. Finally, miRNAs were quantified by real-time PCR
using TaqMan miRNA assays (Applied Biosystems, Foster
City, CA, USA), according to the manufacturer’s instructions.
Currently, there is no consensus on the selection of
endogenous control for investigating plasma miRNA levels
using real-time PCR. Some researchers have suggested that
miRNA-16, which was previously validated in cancer patients,
seems to be a reliable internal control for circulating miRNAs
[12]. Therefore, our data were standardized to plasma
miRNA-16 levels. Meanwhile, triplicate samples were used
throughout. Relative expression of miRNA was calculated
using the 2-ΔΔCt method [30]. The Ct values from real-time PCR
assays greater than 35 were treated as not expressed.
Statistical Analysis
Comparisons between cases and controls were computed by
Chi-square (categorical variables), student t test (continuous
variables, normal distribution), or Mann-Whitney U test
(continuous variables, skewed distribution). Plasma HO-1
concentrations, circulating miRNA-146a levels, and HOMA-
beta were natural log–transformed prior to general linear
regression analysis. Multivariate logistic regression analysis
was used to assess the association of new-T2DM with
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miRNA-146a levels. For calculation of odds ratios (ORs) and
95% confidence intervals (CI) for new-T2DM, circulating
miRNA-146a levels and plasma HO-1 concentrations were
categorized into tertiles based on the distribution in the control
group. ORs and 95% CIs were adjusted for known risk factors
of T2DM, including age, sex, BMI, smoking, alcohol drinking,
history of hypertension, family history of diabetes, and some
biochemical indicators. Area under the curve (AUC) using
receiver operating characteristic (ROC) analysis was calculated
for miNRA-146a to assess predictive value. A 2-tailed P value
< 0.05 was considered significant. The differences in areas
under ROC curves for logistic regression models were
conducted with STATA version 11 (Stata-Corp, College
Station, Texas), and all other statistical analyses were
performed using SPSS for Windows software version 12.0
(SPSS Inc, Chicago, IL, USA).
Results
This study consisted of 90 new-T2DM cases and 90 age-
and sex-matched controls. Demographic and clinical
characteristics of the study subjects are shown in Table 1. BMI
was significantly higher in new-T2DM patients than in controls.
More controls than new-T2DM patients were alcohol drinkers.
However, the percentage of persons with hypertension and
family history of diabetes differed significantly between cases
and controls. In addition, cases and controls had statistically
different laboratory results for TG (P = 0.040), FPG, FPI,
HOMA-beta, HOMA-IR, and plasma HO-1 concentrations (P <
0.001).
Using miRNA-16 as a normalization control, we found a
more robustly elevated expression of circulating miRNA-146a
in participants with new-T2DM than among controls (P < 0.001)
(Figure 1). Subsequently, we assessed the ORs for new-T2DM
associated with circulating miRNA-146a levels, which were
categorized into tertiles according to their distribution among
the controls (Table 2). Increased ORs were observed for new-
T2DM in relation to higher level of circulating miRNA-146a
levels. Participants in the highest tertile of circulating
miRNA-146a levels were at significantly elevated risk for new-
T2DM (crude OR 4.333, 95% CI, 1.935 to 9.705, P < 0.001)
compared with persons in the lowest tertile. The result was not
altered after adjusting for age, sex, and BMI or further for
smoking, alcohol drinking, disease history, and some
biochemical indicators. Additional adjustment for plasma HO-1
concentrations slightly attenuated the above relationship
(adjusted OR 3.832, 95% CI, 1.505 to 9.759, P = 0.010).
In the ROC analysis, miRNA-146a distinguished new-T2DM
patients from controls with an AUC of 0.725 (95% CI, 0.651 to
0.799, P < 0.001). We then performed the comparisons among
models with or without plasma HO-1 concentrations and
circulating miRNA-146a levels (Figure 2). The AUC for the
conventional model, comprising age, sex, BMI, smoking,
alcohol drinking, history of hypertension, family history of
diabetes, TC, TG, HDL-C, and LDL-C was 0.753 (95% CI,
0.679 to 0.827) for new-T2DM. When circulating miRNA-146a
levels were added to the model, the AUC was increased to
0.844 (95% CI, 0.785 to 0.903, P = 0.0005 for the difference of
AUCs with conventional model). After plasma HO-1
concentration and circulating miRNA-146a levels were
introduced, the AUC increased significantly to 0.865 (95% CI,
0.813 to 0.917), compared with conventional model (P =
0.0001) or conventional model plus plasma HO-1 concentration
(P = 0.0054).
We examined circulating miRNA-146a levels for possible
association with concentrations of plasma HO-1 and HOMA-
beta after natural log-transformation (Table 3). Higher
circulating miRNA-146a levels were significantly associated
with higher plasma HO-1 concentrations (β coefficient = 0.131,
P < 0.001). The observed effect size of circulating miRNA-146a
levels on plasma HO-1 concentrations did not change after
adjusting for age, sex, and BMI (β coefficient = 0.135, P <
0.001). This association persisted after adjustment for other
diabetes risk factors (β coefficient = 0.119, P < 0.001). We
observed a significant inverse association between circulating
miRNA-146a levels and HOMA-beta (multivariate β coefficient
= -0.137, P = 0.023). However, no association was observed
between circulating miRNA-146a and HOMA-IR.
Discussion
In this study, we observed a significant positive association
between levels of circulating miRNA-146a and risk of new-
T2DM patients. When circulating miRNA-146a levels were
added to the conventional model, the AUC was significantly
Table 1. Characteristics of the participants*.
Characteristics New-T2DM patients Controls P value
No. of subjects 90 90  
Age, years 48.50 (42.00-56.00) 48.00 (41.75-55.00) 0.416
Male, n (%) 47 (52.22) 47 (52.22) 1.000
BMI, kg/m2 24.58 (3.66) 23.38 (2.95) 0.016
Smoking, n (%) 26 (28.89) 35 (38.89) 0.156
Alcohol drinking, n (%) 14 (15.56) 26 (28.89) 0.031
FH of Diabetes, n (%) 24 (26.67) 11 (12.22) 0.014
Hypertension, n (%) 32 (35.56) 17 (18.89) 0.012
TC (mmol/l) 4.98 (1.06) 4.83 (1.01) 0.342
TG (mmol/l) 1.47 (1.10-2.14) 1.35 (1.01-1.79) 0.040
HDL-C (mmol/l) 1.06 (0.93-1.24) 1.13 (0.88-1.38) 0.375
LDL-C (mmol/l) 3.19 (0.93) 3.16 (0.97) 0.828
FPG (mmol/l) 7.41 (6.76-12.37) 5.24 (5.01-5.53) <0.001
FPI (μU/ml) 9.20 (5.42-14.92) 6.18 (4.74-8.76) <0.001
HOMA-beta 37.82 (19.98-71.70) 74.72 (47.28-113.94) <0.001
HOMA-IR 3.47 (2.04-5.50) 1.52 (1.10-2.08) <0.001
HO-1 (ng/ml) 2.02 (1.68-2.47) 1.63 (1.13-1.98) <0.001
*. Data are presented as number (percentage) for categorical data, mean
(standard deviation) for parametrically distributed data, or median (interquartile
range) for nonparametrically distributed data.
Abbreviations: BMI, body mass index; FH, family history; FPG, fasting plasma
glucose; FPI, fasting plasma insulin; HDL-C, high-density lipoprotein-cholesterol;
HO-1, heme oxygenase-1; HOMA-beta, homeostasis model assessment of beta
cell function; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-
C, low-density lipoprotein-cholesterol; New-T2DM, newly diagnosed type 2
diabetes mellitus; TC, total cholesterol; TG, triglycerides.
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increased. Additionally, circulating miRNA-146a levels were
positively related to plasma concentrations of HO-1, a protein
that may be targeted by miRNA-146a. Moreover, circulating
miRNA-146a levels were inversely associated with HOMA-
beta. However, no significant relationship between circulating
miRNA-146a levels and HOMA-IR was detected. In our study,
the relative levels of circulating miRNA-146a were calculated
using the 2-ΔΔCt method and the sample size was relatively
small, therefore, the variations were quite wide.
MiRNA-146a, one of the inflammation-related miRNAs,
contains fingerprints for various diseases and has been
reported to predict immunological diseases and cancers, such
as gastric cancer [31], hepatocellular carcinoma [32], and
Sjogren’s syndrome [33]. In addition, miRNA-146a may also be
involved in the pathological processes of inflammatory human
degenerative diseases, such as Prion disease [34,35],
Alzheimer’s disease [36,37] and Epilepsy [38,39].
However, few studies have investigated the relationship
between this marker and diabetes pathogenesis. On the other
hand, the role of miRNA-146a in the pathogenesis of
inflammation and other degenerative aspects may make it
participate in the course of T2DM. McMillan et al. reported that
in RelB-depleted fibroblasts, after miR-146a overexpression,
IL-1β-induced IL-6 production was also significantly reduced
[40]. In addition, in human gingival fibroblasts, the inhibition of
miRNA-146a resulted in increased IL-1β, IL-6 and TNF-α
secretion, which suggested that miRNA-146a functions as a
negative regulator of periodontal inflammation [41]. Moreover,
miRNA-146a-mediated down-regulation of interleukin-1
receptor-associated kinase-1 together with NF-κB-induced up-
regulation of interleukin-1 receptor-associated kinase-2
expression could promote an extensively sustained
inflammatory response in hippocampus and neocortex of
Alzheimer disease brain and in interleukin-1β and amyloid-β-42
peptide-stressed human astroglial cells [36]. The positive
Figure 1.  Circulating miRNA-146a levels in controls and new-T2DM patients.  Data are shown as median (interquartile range).
*P < 0.05 compared to controls.
Abbreviations: new-T2DM, newly diagnosed type 2 diabetes mellitus.
doi: 10.1371/journal.pone.0073272.g001
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association between circulating miRNA-146a levels and new-
T2DM risk observed in our study is consistent with that from a
previous case-control study conducted in a Chinese sample
[42]. However, our study had a much larger sample size and
used persons participating in routine health examinations as
controls, instead of T2DM-susceptible individuals with normal
glucose tolerance. In addition, our study found that circulating
miRNA-146a levels were inversely associated with HOMA-
beta.
In a study conducted in Italy, Zampetaki et al. [19] identified
no notable association between circulating miRNA-146a levels
and T2DM, using microarray screening of pooled plasma
samples of diabetes cases and controls. Several factors may
explain the discrepancies between our findings and this study.
First, our study was focused on miRNA-146a levels, whereas
Zampetaki et al. conducted an exploratory analysis of multiple
microRNAs. Second, differences in race and ethnicity may
contribute to the divergence. It is well-known that race and
ethnicity are reflected in distinct sequencing of the human
genome and the mapping of human genetic variation [43]. As a
key regulator of gene expression, the expression profiles of
miRNAs probably vary among participants of different races or
Table 2. Odds ratios (95% CI) for new-T2DM, by tertiles of
plasma miRNA-146a levels.
Variable Tertiles of plasma miRNA-146a levels P - trend
 1 (Lowest)2 3 (Highest)  
MiRNA-146a levels <0.740 0.740-1.339 ≥1.339  
New-T2DM patients/
Controls, n/n 12/30 26/30 52/30  
Crude OR (95% CI) 1 2.167(0.925-5.074)
4.333
(1.935-9.705) 0.001
Adjusted OR (95%
CI), Model 1* 1
2.413
(0.997-5.842)
4.938
(2.129-11.456) <0.001
Adjusted OR (95%
CI), Model 2* 1
2.312
(0.918-5.825)
4.917
(2.044-11.828) 0.001
Adjusted OR (95%
CI), Model 3* 1
1.978
(0.760-5.151)
4.815
(1.968-11.780) 0.001
Adjusted OR (95%
CI), Model 4* 1
1.757
(0.646-4.781)
3.832
(1.505-9.759) 0.010
*. Model 1, adjusted for age, sex and BMI; Model 2, adjusted for Model 1, smoking,
alcohol drinking, family history of diabetes and hypertension; Model 3, adjusted for
Model 2, TC, TG, HDL-C and LDL-C; Model 4, adjusted for Model 3 and HO-1
concentration.
Abbreviations: BMI, body mass index; CI, confidence interval; HDL-C, high-density
lipoprotein-cholesterol; HO-1, heme oxygenase-1; LDL-C, low-density lipoprotein-
cholesterol; New-T2DM, newly diagnosed type 2 diabetes mellitus; OR, odds ratio;
TC, total cholesterol; TG, triglycerides.
ethnicities. Finally, we considered only new-T2DM patients as
cases to avoid possible confounding effects of anti-diabetic
medications, while the diabetes cases in Zampetaki et al. were
diagnosed during a certain period of follow-up time.
Heme oxygenase-1 (HO-1) has been found to exert its anti-
inflammatory, anti-oxidant, and anti-proliferative effects on
plenty of physiological and pathological processes [24]. Our
previous study suggested that elevated plasma HO-1
concentrations were associated with higher risk for new-T2DM,
likely in a dose–response manner [25]. Recently, Kozakowska
and colleagues sought to examine the relationship between
HO-1 and miRNA processing [26]. It was brought to light that
activation of HO-1 in C2C12 cells increased production of
miR-146a, regardless of the mode of stimulation. This view is
corroborated by our findings that circulating miRNA-146a levels
were correlated with plasma HO-1 concentrations and that the
expression of miRNA-146a was notably higher in new-T2DM
patients than controls. However, whether increased circulating
miRNA-146a is caused by increased plasma HO-1
concentrations or other mechanisms remains unknown. On the
other hand, Balasubramanyam and colleagues evaluated the
role of miR-146a expression in peripheral blood mononuclear
cells (PBMC) in relation to glycemic control and insulin
resistance in both T2DM patients and non-diabetic subjects
[44]. Intriguingly, the expression levels of miR-146a were
significantly decreased in PBMCs from T2DM patients
compared with cells from control subjects. The sources of
circulating miRNAs may contribute to the above discrepancy.
Consensus has not yet been reached, but several studies have
addressed whether circulating miNRAs are derived not only
from blood cells but also from tissues affected by disease [45].
Some limitations of this study should be acknowledged. First,
we focused solely on the association between circulating
miRNA-146a levels and new-T2DM and did not explore other
miRNAs. In addition, the stratified analyses by some risk
factors, such as family history of diabetes, were hampered due
to the small numbers of participants available in subgroups.
Furthermore, the expression levels of miRNA-146a may be
affected by multiple factors. In our study, circulating
miRNA-146a levels were found to be correlated with plasma
HO-1 concentrations. However, we could not establish a
cause-effect relationship or provide insight into the molecular
mechanisms underlying the regulatory action of circulating
miRNA-146a.
In conclusion, we found that circulating miRNA-146a levels
were elevated in new-T2DM patients compared with controls.
This association needs to be confirmed in future studies. In
addition, the biological mechanisms and whether expression of
circulating miRNA-146a holds predictive value for T2DM
warrants further investigations.
Circulating miRNA-146a Levels and New-T2DM
PLOS ONE | www.plosone.org 5 September 2013 | Volume 8 | Issue 9 | e73272
Figure 2.  ROC curves and corresponding AUCs for new-T2DM.  The AUC in an established conventional model was 0.753
(95% CI, 0.679 to 0.827), and that in a model with plasma HO-1 concentration plus the established conventional model was 0.813
(95% CI, 0.750 to 0.876). After circulating miRNA-146a levels were introduced, the AUC was 0.844 (95% CI, 0.785 to 0.903). In
addition, the AUC of all parameters included was 0.865 (95% CI, 0.813 to 0.917); P = 0.0009 for the differences of the above AUCs.
The established conventional model here consists of age, sex, BMI, smoking, alcohol drinking, hypertension, and family history of
diabetes, TC, TG, HDL-C and LDL-C.
Abbreviations: AUC, area under the curve; BMI, body mass index; CI, confidence interval; HDL-C, high-density lipoprotein-
cholesterol; HO-1, heme oxygenase-1; LDL-C, low-density lipoprotein-cholesterol; new-T2DM, newly diagnosed type 2 diabetes
mellitus; ROC, receiver operating characteristic; TC, total cholesterol; TG, triglycerides.
doi: 10.1371/journal.pone.0073272.g002
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Table 3. Associations of circulating miRNA-146 levels with
plasma HO-1 concentrations and HOMA-beta.
MiRNA-146a levels* HO-1 concentrations (ng/ml)* HOMA-beta*
 β (SE) P β (SE) P
Crude 0.131 (0.030) <0.001 -0.153 (0.062) 0.015
Adjusted, model 1† 0.135 (0.029) <0.001 -0.152 (0.059) 0.011
Adjusted, model 2† 0.123 (0.029) <0.001 -0.149 (0.060) 0.014
Adjusted, model 3† 0.119 (0.029) <0.001 -0.137 (0.059) 0.023
*. Natural log-transformed before analysis
† Model 1, adjusted for age, sex and BMI; Model 2, adjusted for Model 1, smoking,
alcohol drinking, family history of diabetes and hypertension; Model 3, adjusted for
Model 2, TC, TG, HDL-C and LDL-C
Abbreviations: BMI, body mass index; HDL-C, high-density lipoprotein-cholesterol;
HO-1, heme oxygenase-1; HOMA-beta, homeostasis model assessment of beta
cell function; LDL-C, low-density lipoprotein-cholesterol; TC, total cholesterol; TG,
triglycerides.
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